TickerStat.comEloxx Pharmaceuticals annual ebitda margin
2010
2012
2013
2014
2024
Eloxx Pharmaceuticals EBITDA Margin Growth & History (ELOX)
Eloxx Pharmaceuticals's ebitda margin was −38.26% for fiscal 2024.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −38.26% | — |
| 2014 | 2014-06-30 | −4,828.07% | +50893.52 pp |
| 2013 | 2013-06-30 | −55,721.59% | −53144.84 pp |
| 2012 | 2012-06-30 | −2,576.75% | — |
| 2010 | 2010-06-30 | −3,371.40% | — |
Eloxx Pharmaceuticals quarterly ebitda margin
Q2.12
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2012 | 2011-12-31 | −697.24% | — |
Eloxx Pharmaceuticals ebitda margin trends
Between the periods ended 2010-06-30 and 2024-12-31, Eloxx Pharmaceuticals's ebitda margin increased from −3,371.40% to −38.26%, a change of +3333.14 percentage points. The latest reported quarter, Q2 2012, shows −697.24%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...